<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445796</url>
  </required_header>
  <id_info>
    <org_study_id>PM_L_0163</org_study_id>
    <nct_id>NCT00445796</nct_id>
  </id_info>
  <brief_title>Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance</brief_title>
  <acronym>ATOL</acronym>
  <official_title>Randomised, Comparative Study of the Efficacy and Safety of Arsucam® Administered as a Single Daily Intake Versus Two Daily Intakes in the Treatment of Plasmodium Falciparum Malaria Attack</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To demonstrate the non-inferiority, in terms of clinical and parasitological efficacy on Day&#xD;
      14, of administration of Arsucam® as a single daily intake versus two daily intakes.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      To compare the clinical safety of the two treatment regimens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical and parasitological cure on Day 14</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Secondary: incidence and severity of adverse events</measure>
  </primary_outcome>
  <enrollment>300</enrollment>
  <condition>Malaria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amodiaquine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  weighing ≥ 10 kg&#xD;
&#xD;
          -  residing in the area covered by the investigating centre throughout the entire&#xD;
             follow-up period&#xD;
&#xD;
          -  axillary temperature ≥ 37.5 degrees Celsius or history of fever within the previous 24&#xD;
             hours&#xD;
&#xD;
          -  Plasmodium falciparum density in the blood ranging from 1000 to 100,000 asexual forms&#xD;
             per cubic millimetre&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence of at least one sign of severe malaria or clinical danger sign : prostration,&#xD;
             consciousness disorders, recent and repeated convulsions , respiratory distress,&#xD;
             inability to drink, uncontrollable vomiting, macroscopic haemoglobinuria, jaundice,&#xD;
             haemorrhagic shock, systolic Blood Pressure &lt; 70 mmHg in adults or &lt; 50 in children,&#xD;
             spontaneous bleeding, inability to sit or stand&#xD;
&#xD;
          -  serious concomitant disease&#xD;
&#xD;
          -  allergy to one of the investigational medicinal products&#xD;
&#xD;
          -  pregnant women or breast-feeding women.&#xD;
&#xD;
          -  documented intake of an antimalarial at a suitable dosage within seven days prior to&#xD;
             inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie Lameyre</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Yaounde</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
    <country>Senegal</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>March 8, 2007</study_first_submitted>
  <study_first_submitted_qc>March 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2007</study_first_posted>
  <last_update_submitted>April 8, 2008</last_update_submitted>
  <last_update_submitted_qc>April 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Amodiaquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

